SUDO 643
Alternative Names: SUDO-643Latest Information Update: 02 Jan 2024
At a glance
- Originator Sudo Biosciences
- Class Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 02 Jan 2024 Preclinical trials in Autoimmune disorders in USA (PO) (Sudo Biosciences pipeline, January 2024)